A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel

Abdel Salam Attia Ismail, Mary G. Quinn, Maurice A. Wright, Aaron Ernst, Vivian Kao, Liam Grogan, Allison Parr, Frank Grollman, Ilan R. Kirsch, Jean L. Grem

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon α-2a (IFN-α). This phase II study assessed the antitumor efficacy of this regimen. Patients (n=38) with colorectal cancer received IFN-α 5 MU/m2 SC on days 1-6; on days 2-6, LV 200 mg/m2 IV was given with 5-FU at initial doses of 370-425 mg/m2/h. The regimen was well-tolerated with no grade 4 toxicity. At 425 mg/m2 5-FU, grade 3 toxicities included diarrhea (8.6%), anorexia, fever and fatigue (5.7% each), neutropenia and nausea/vomiting (2.9% each). Individuals tolerated 5-FU doses up to 644 mg/m2. Objective responses occurred in 27% of 37 patients; median time to progression and survival were 6.1 and 12.9 months. Only 1 of 25 informative tumor samples had high-frequency microsatellite instability (MSI), while 7 of 23 assessable patients (30%) with MSI-negative tumors had an objective response. With 425 mg/m2, the average 5-FU Cp and AUC 0-1 h were 37.4 μM and 1161 μM/h. Some 6 patients had extended sampling, and the half-lives of 5-FU and FBAL (apparent) were 8.6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose.

Original languageEnglish (US)
Pages (from-to)1145-1152
Number of pages8
JournalOncology reports
Volume13
Issue number6
StatePublished - Jun 1 2005

Fingerprint

Leucovorin
Fluorouracil
Interferons
Adenocarcinoma
Microsatellite Instability
Anorexia
Neutropenia
Nausea
Area Under Curve
Vomiting
Fatigue
Colorectal Neoplasms
Diarrhea
Neoplasms
Fever
Survival

Keywords

  • Adenocarcinoma
  • Fluorouracil
  • Interferon α-2a
  • Large bowel
  • Leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel. / Ismail, Abdel Salam Attia; Quinn, Mary G.; Wright, Maurice A.; Ernst, Aaron; Kao, Vivian; Grogan, Liam; Parr, Allison; Grollman, Frank; Kirsch, Ilan R.; Grem, Jean L.

In: Oncology reports, Vol. 13, No. 6, 01.06.2005, p. 1145-1152.

Research output: Contribution to journalArticle

Ismail, ASA, Quinn, MG, Wright, MA, Ernst, A, Kao, V, Grogan, L, Parr, A, Grollman, F, Kirsch, IR & Grem, JL 2005, 'A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel', Oncology reports, vol. 13, no. 6, pp. 1145-1152.
Ismail, Abdel Salam Attia ; Quinn, Mary G. ; Wright, Maurice A. ; Ernst, Aaron ; Kao, Vivian ; Grogan, Liam ; Parr, Allison ; Grollman, Frank ; Kirsch, Ilan R. ; Grem, Jean L. / A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel. In: Oncology reports. 2005 ; Vol. 13, No. 6. pp. 1145-1152.
@article{634109c46714422c829216d33ad37ad4,
title = "A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel",
abstract = "We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon α-2a (IFN-α). This phase II study assessed the antitumor efficacy of this regimen. Patients (n=38) with colorectal cancer received IFN-α 5 MU/m2 SC on days 1-6; on days 2-6, LV 200 mg/m2 IV was given with 5-FU at initial doses of 370-425 mg/m2/h. The regimen was well-tolerated with no grade 4 toxicity. At 425 mg/m2 5-FU, grade 3 toxicities included diarrhea (8.6{\%}), anorexia, fever and fatigue (5.7{\%} each), neutropenia and nausea/vomiting (2.9{\%} each). Individuals tolerated 5-FU doses up to 644 mg/m2. Objective responses occurred in 27{\%} of 37 patients; median time to progression and survival were 6.1 and 12.9 months. Only 1 of 25 informative tumor samples had high-frequency microsatellite instability (MSI), while 7 of 23 assessable patients (30{\%}) with MSI-negative tumors had an objective response. With 425 mg/m2, the average 5-FU Cp and AUC 0-1 h were 37.4 μM and 1161 μM/h. Some 6 patients had extended sampling, and the half-lives of 5-FU and FBAL (apparent) were 8.6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose.",
keywords = "Adenocarcinoma, Fluorouracil, Interferon α-2a, Large bowel, Leucovorin",
author = "Ismail, {Abdel Salam Attia} and Quinn, {Mary G.} and Wright, {Maurice A.} and Aaron Ernst and Vivian Kao and Liam Grogan and Allison Parr and Frank Grollman and Kirsch, {Ilan R.} and Grem, {Jean L.}",
year = "2005",
month = "6",
day = "1",
language = "English (US)",
volume = "13",
pages = "1145--1152",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel

AU - Ismail, Abdel Salam Attia

AU - Quinn, Mary G.

AU - Wright, Maurice A.

AU - Ernst, Aaron

AU - Kao, Vivian

AU - Grogan, Liam

AU - Parr, Allison

AU - Grollman, Frank

AU - Kirsch, Ilan R.

AU - Grem, Jean L.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon α-2a (IFN-α). This phase II study assessed the antitumor efficacy of this regimen. Patients (n=38) with colorectal cancer received IFN-α 5 MU/m2 SC on days 1-6; on days 2-6, LV 200 mg/m2 IV was given with 5-FU at initial doses of 370-425 mg/m2/h. The regimen was well-tolerated with no grade 4 toxicity. At 425 mg/m2 5-FU, grade 3 toxicities included diarrhea (8.6%), anorexia, fever and fatigue (5.7% each), neutropenia and nausea/vomiting (2.9% each). Individuals tolerated 5-FU doses up to 644 mg/m2. Objective responses occurred in 27% of 37 patients; median time to progression and survival were 6.1 and 12.9 months. Only 1 of 25 informative tumor samples had high-frequency microsatellite instability (MSI), while 7 of 23 assessable patients (30%) with MSI-negative tumors had an objective response. With 425 mg/m2, the average 5-FU Cp and AUC 0-1 h were 37.4 μM and 1161 μM/h. Some 6 patients had extended sampling, and the half-lives of 5-FU and FBAL (apparent) were 8.6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose.

AB - We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon α-2a (IFN-α). This phase II study assessed the antitumor efficacy of this regimen. Patients (n=38) with colorectal cancer received IFN-α 5 MU/m2 SC on days 1-6; on days 2-6, LV 200 mg/m2 IV was given with 5-FU at initial doses of 370-425 mg/m2/h. The regimen was well-tolerated with no grade 4 toxicity. At 425 mg/m2 5-FU, grade 3 toxicities included diarrhea (8.6%), anorexia, fever and fatigue (5.7% each), neutropenia and nausea/vomiting (2.9% each). Individuals tolerated 5-FU doses up to 644 mg/m2. Objective responses occurred in 27% of 37 patients; median time to progression and survival were 6.1 and 12.9 months. Only 1 of 25 informative tumor samples had high-frequency microsatellite instability (MSI), while 7 of 23 assessable patients (30%) with MSI-negative tumors had an objective response. With 425 mg/m2, the average 5-FU Cp and AUC 0-1 h were 37.4 μM and 1161 μM/h. Some 6 patients had extended sampling, and the half-lives of 5-FU and FBAL (apparent) were 8.6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose.

KW - Adenocarcinoma

KW - Fluorouracil

KW - Interferon α-2a

KW - Large bowel

KW - Leucovorin

UR - http://www.scopus.com/inward/record.url?scp=24744438521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744438521&partnerID=8YFLogxK

M3 - Article

C2 - 15870935

AN - SCOPUS:24744438521

VL - 13

SP - 1145

EP - 1152

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -